Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study

The introduction of the so-called immune checkpoint inhibitors (ICIs) substantially changed the history of cancer therapy. On the other hand, they can induce the development of rheumatic immune-related adverse events (Rh-irAEs). In the scenario of a joint oncology/rheumatology outpatient clinic, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceccarelli, Fulvia, Natalucci, Francesco, Picciariello, Licia, Olivieri, Giulio, Cirillo, Alessio, Gelibter, Alain, Picone, Vincenzo, Botticelli, Andrea, Conti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141051/
https://www.ncbi.nlm.nih.gov/pubmed/37109406
http://dx.doi.org/10.3390/life13040877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141051/
https://www.ncbi.nlm.nih.gov/pubmed/37109406
http://dx.doi.org/10.3390/life13040877

Ejemplares similares